A virus within a virus, and it's been largely neglected
In the long effort to address diseases that medicine has struggled to reach, Vir Biotechnology has completed enrollment in a pivotal Phase 3 trial testing a two-drug combination against chronic hepatitis delta — a rare liver disease that has resisted effective treatment for decades. The trial, ECLIPSE 1, pairs two agents designed to attack the virus from multiple angles simultaneously, a strategy that both the FDA and European regulators have already recognized as promising through a series of expedited designations. The world will wait until early 2027 to learn whether this approach can translate scientific confidence into a genuine cure for patients whose options have long been few.
- Hepatitis delta infects only those already carrying hepatitis B, yet it accelerates liver destruction far beyond what hepatitis B alone causes — making it one of the most dangerous and neglected viral diseases in medicine.
- Vir's two-drug combination targets the virus at multiple points in its lifecycle, a deliberate strategy to prevent the pathogen from adapting around a single line of attack.
- Regulators on both sides of the Atlantic have signaled unusual confidence: the FDA granted Breakthrough Therapy and Fast Track designations, while the EMA awarded Priority Medicines and orphan drug status — a rare alignment of institutional urgency.
- With enrollment now closed, the trial enters its most consequential phase — a waiting period in which the last patients complete treatment and data accumulates toward a primary endpoint expected in late 2026.
- Topline results arriving in Q1 2027 will determine whether Vir can file for approval in the U.S. and Europe, or whether the company must reckon with a more difficult path forward.
Vir Biotechnology has closed enrollment in ECLIPSE 1, a Phase 3 trial testing whether a two-drug combination — tobevibart paired with elebsiran — can treat chronic hepatitis delta, a rare and serious liver infection that has long resisted effective therapy. The two drugs work through distinct mechanisms, targeting different points in the virus's lifecycle in a strategy designed to overwhelm its ability to adapt and survive. ECLIPSE 1 is the centerpiece of Vir's broader ECLIPSE program and the trial expected to generate the regulatory data needed for approval in the United States and Europe.
Hepatitis delta is a particularly stubborn disease. It only infects people already carrying hepatitis B, yet it accelerates liver damage far beyond what hepatitis B causes alone — progressing silently toward cirrhosis and liver failure in many patients. Existing options have been limited and often ineffective, making the unmet medical need acute.
Regulators have already signaled confidence in Vir's direction. The FDA granted both Breakthrough Therapy and Fast Track designations, reserved for drugs addressing serious conditions with meaningful preliminary evidence of advantage. The European Medicines Agency awarded Priority Medicines status and orphan drug designation, the latter an acknowledgment that hepatitis delta affects a small population requiring special incentives to bring a treatment to market.
The trial now enters a waiting period. The last enrolled patient is expected to reach the primary endpoint in Q4 2026, with topline results — the first public readout of whether the drugs worked — anticipated in Q1 2027. Those results will determine whether Vir moves forward with regulatory submissions in major markets, and whether patients living with chronic hepatitis delta may finally have a treatment capable of eliminating the virus entirely.
Vir Biotechnology has closed enrollment in ECLIPSE 1, a pivotal Phase 3 trial designed to test whether a two-drug combination can treat chronic hepatitis delta, a rare and serious liver infection that has long lacked effective therapies. The trial is evaluating tobevibart paired with elebsiran—drugs that work through different mechanisms to disrupt how the hepatitis delta virus replicates and survives in the body. This is one of three trials in Vir's broader ECLIPSE program, but ECLIPSE 1 is the one expected to generate the regulatory data needed for approval in the United States and Europe.
Hepatitis delta is a particularly difficult disease. It only infects people who already carry hepatitis B, and it accelerates liver damage in ways that hepatitis B alone does not. The virus has proven stubborn to treat, and for many patients, options have been limited or ineffective. The combination Vir is testing targets the virus at multiple points in its lifecycle—a strategy designed to overwhelm the pathogen's ability to adapt and survive. The company's approach reflects a growing recognition in virology that hitting a virus from several angles at once can be more powerful than single-drug therapy.
The regulatory pathway has already signaled confidence in this direction. The FDA granted the combination both Breakthrough Therapy and Fast Track designations, labels the agency reserves for drugs addressing serious conditions where preliminary evidence suggests meaningful advantage over existing treatments. The European Medicines Agency went further, awarding Priority Medicines status and orphan drug designation—the latter a recognition that hepatitis delta affects a small population and that bringing a treatment to market requires special incentives and support.
The timeline now moves into a waiting period. The last patient enrolled in ECLIPSE 1 is expected to complete the trial's primary endpoint—the moment when enough data has accumulated to assess whether the drugs worked—sometime in the fourth quarter of 2026. Topline results, the first public readout of what the trial found, should arrive in the first quarter of 2027. These results will determine whether Vir can move forward with regulatory submissions in major markets, or whether the company will need to reconsider its approach.
For patients with chronic hepatitis delta, the stakes are high. The disease progresses silently in many cases, causing cirrhosis and liver failure without obvious warning. A treatment that could eliminate the virus entirely—which is what Vir's combination is designed to do—would represent a genuine shift in how the disease is managed. The completion of enrollment suggests the trial is on track, and that within roughly a year, the field will have concrete evidence about whether this particular strategy works.
Notable Quotes
The objective is to eliminate the virus, and tobevibart in combination with elebsiran offers the potential to achieve this by tackling the viral lifecycle through multiple mechanisms.— Vir Biotechnology
The Hearth Conversation Another angle on the story
Why does hepatitis delta need its own trial when hepatitis B treatments already exist?
Because hepatitis delta only infects people who already have hepatitis B, and it makes everything worse—it accelerates liver damage in ways B alone doesn't. Existing hepatitis B drugs often don't touch delta. It's a virus within a virus, and it's been largely neglected because the patient population is small.
So the two drugs in this trial work differently from each other?
Exactly. Tobevibart and elebsiran attack the virus through separate mechanisms. The idea is that by hitting it from multiple angles, you overwhelm its ability to adapt and survive. Single drugs often fail because the virus mutates around them.
What does it mean that the FDA gave it Breakthrough Therapy status?
It means the FDA looked at early evidence and said this combination shows real promise for a serious disease where current options are inadequate. It's a signal that the agency is paying attention and will work with Vir to move things along faster than usual.
When will we actually know if it works?
The last patient should finish the trial by the end of 2026, and Vir will release the main results in early 2027. That's when we'll see whether the combination actually eliminates the virus or just slows it down.
What happens if the results are negative?
Then Vir goes back to the drawing board. But the regulatory support—the Breakthrough designation, the orphan drug status—suggests there's genuine belief this could work. The bar for approval in rare diseases is often lower because the need is so acute.